? MICROSCOPY SHARED RESOURCE (MSR) The MSR provides timely and high-quality services to support OSUCCC investigators with access to instrument, technical advice and training support on a variety of sophisticated microscopy approaches. The MSR instrumentation is provided in a centrally-organized resource and all the equipment is available to OSUCCC membership with training. At the last review, the MSR was part of the Diagnostics Shared Resource Group, which was rated as Outstanding with minor comments about leadership and usage that have been addressed. During the current grant cycle, there was a significant investment in acquiring electron microscopy (cryogenic, transmission and scanning electron microscopes) and confocal live cell imaging, including enhanced super- resolution (SIM, STORM, TIRF) light microscopy capabilities funded through an NIH S10 equipment grant.
The Specific Aims of the MSR are to: 1) provide a means for OSUCCC research community to obtain publication quality, higher resolution images of their cancer research for use in manuscripts and grant applications; 2) provide training to investigators for independent use of the instruments following training; 3) provide education and consultation opportunities to OSUCCC researchers for improved sample preparation, imaging techniques and image analysis; and, as a Developing Aim to provide OSUCCC members access to cryo-electron microscopy (cryo-EM). For this Developing Aim, the OSCUCC contributed to the purchase of two instruments with sub- nanometer resolution of purified and cellular particles. During the five-year grant period, the MSR has supported 319 investigators (32% OSUCCC members), and provided 5,730 hours of service and 44,605 hours of instrument time (33.3% of which was to OSUCCC members). The MSR contributed to 192 publications (32 > 10 impact factor) and 8 NCI grants (2 K22s, 1 P01, 1 P50, 8 R01s, and 1 U01). The MSR will support the microscopy needs of all OSUCCC strategic priorities. Given the robust OSUCCC recruitment, demand for services and new technologies will increase and capacity will be expanded. To align with immuno-oncology needs, the MSR will be a regular member of the Immune Monitoring and Discovery Platform (IMDP), and two-photon microscopes will be updated. Separately, the MSR is developing cryo-FIB capability for CET studies, and it will develop correlative light and electron microscopy and real-time single molecule cellular imaging platforms in collaboration with the GEdSR. Last, the MSR and GSR has been awarded a new grant to provide imaging capabilities that supports cell enrichment and single cell sequencing. The MSR is supported by outstanding institutional resources obtained by leveraging extensive partnerships with the OSUCCC, OSU Colleges, the OSU Office of Research and grants from the State of Ohio, all totaling over $2M over the prior grant period. The annual budget of the MSR is $697,706, yet the CCSG request is $82,192. As such, the MSR seeks only 11.8% budgetary support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090014
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Nyankima, A Gloria; Rojas, Juan D; Cianciolo, Rachel et al. (2018) In Vivo Assessment of the Potential for Renal Bio-Effects from the Vaporization of Perfluorocarbon Phase-Change Contrast Agents. Ultrasound Med Biol 44:368-376

Showing the most recent 10 out of 2602 publications